代谢谱分析可确定肺肿瘤对厄洛替尼的反应性。
Metabolic profiling identifies lung tumor responsiveness to erlotinib.
作者信息
Fan Teresa W-M, Lane Andrew N, Higashi Richard M, Bousamra Michael, Kloecker Goetz, Miller Donald M
机构信息
Department of Chemistry University of Louisville, Louisville, KY 40208, USA.
出版信息
Exp Mol Pathol. 2009 Aug;87(1):83-6. doi: 10.1016/j.yexmp.2009.04.004. Epub 2009 May 3.
Abstract
A subtype of non-small cell lung cancer, bronchioalveolar adenocarcinoma (BAC), is more prevalent in Asian female non-smokers, and is more likely to respond to treatment with tyrosine kinase inhibitors such as erlotinib and gefitinib. Nuclear magnetic resonance and mass spectrometry-based metabolomic analysis of extracts from two different lung lesions and surrounding non-cancerous tissues of a BAC patient showed novel protein and phospholipid-associated metabolic differences that correlated with tumor development as well as PET and erlotinib sensitivity.
摘要
细支气管肺泡腺癌（BAC）是一种非小细胞肺癌亚型，在亚洲不吸烟女性中更为常见，并且更有可能对诸如厄洛替尼和吉非替尼等酪氨酸激酶抑制剂治疗产生反应。对一名BAC患者的两种不同肺部病变及周围非癌组织提取物进行基于核磁共振和质谱的代谢组学分析，结果显示出与肿瘤发展以及PET和厄洛替尼敏感性相关的新的蛋白质和磷脂相关代谢差异。
相似文献
1
Metabolic profiling identifies lung tumor responsiveness to erlotinib.代谢谱分析可确定肺肿瘤对厄洛替尼的反应性。
Exp Mol Pathol. 2009 Aug;87(1):83-6. doi: 10.1016/j.yexmp.2009.04.004. Epub 2009 May 3.
2
Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.吸烟状态对接受厄洛替尼或吉非替尼治疗的非小细胞肺癌患者无进展生存期和总生存期的影响：一项荟萃分析。
J Clin Pharm Ther. 2015 Dec;40(6):661-71. doi: 10.1111/jcpt.12332. Epub 2015 Nov 17.
3
Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.厄洛替尼治疗日本非小细胞肺癌患者的临床效用：当前证据
Drug Des Devel Ther. 2014 Jul 31;8:1037-46. doi: 10.2147/DDDT.S50358. eCollection 2014.
4
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.厄洛替尼对吉非替尼治疗失败后的非小细胞肺癌患者的挽救治疗临床疗效。
Korean J Intern Med. 2015 Nov;30(6):891-8. doi: 10.3904/kjim.2015.30.6.891. Epub 2015 Oct 30.
5
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).酪氨酸激酶抑制剂对携带少见表皮生长因子受体突变的日本非小细胞肺癌患者的疗效：一项多中心回顾性研究（阪神肿瘤学组0212）结果
Anticancer Res. 2015 Jul;35(7):3885-91.
6
Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.两代患有晚期肺腺癌且对厄洛替尼有持久反应的从不吸烟者。
J Thorac Oncol. 2012 Jul;7(7):1200-1. doi: 10.1097/JTO.0b013e318250ed89.
7
Lung cancer response to gefitinib, then erlotinib, then gefitinib again.肺癌对吉非替尼产生反应，然后对厄洛替尼产生反应，之后又再次对吉非替尼产生反应。
J Thorac Oncol. 2008 Sep;3(9):1077-8. doi: 10.1097/JTO.0b013e318183afb0.
8
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
9
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.在典型的对吉非替尼敏感的亚洲非小细胞肺癌患者中，吉非替尼治疗失败后使用厄洛替尼进行疾病控制的证据。
J Thorac Oncol. 2008 Apr;3(4):400-4. doi: 10.1097/JTO.0b013e318168c801.
10
Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.一名非小细胞肺癌患者携带表皮生长因子受体（EGFR）新型复合突变G719D+L861R对厄洛替尼的反应
J Thorac Oncol. 2013 Sep;8(9):e83-4. doi: 10.1097/JTO.0b013e31829ceb8d.
引用本文的文献
1
Stable isotope-resolved metabolomics analyses of metabolic phenotypes reveal variable glutamine metabolism in different patient-derived models of non-small cell lung cancer from a single patient.稳定同位素分辨代谢组学分析代谢表型揭示了来自单一患者的不同非小细胞肺癌患者衍生模型中可变的谷氨酰胺代谢。
Metabolomics. 2024 Jul 27;20(4):87. doi: 10.1007/s11306-024-02126-x.
2
Metabolomic and proteomic applications to exercise biomedicine.代谢组学和蛋白质组学在运动生物医学中的应用。
Transl Exerc Biomed. 2024 Mar 21;1(1):9-22. doi: 10.1515/teb-2024-2006. eCollection 2024 May.
3
Evaluation of Lung Cancer Patient Response to First-Line Chemotherapy by Integration of Tumor Core Biopsy Metabolomics with Multiscale Modeling.基于肿瘤核心活检代谢组学与多尺度建模整合评估一线化疗的肺癌患者的反应。
Ann Biomed Eng. 2023 Apr;51(4):820-832. doi: 10.1007/s10439-022-03096-8. Epub 2022 Oct 12.
4
Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity.用于预测恶性肿瘤患者对安罗替尼治疗反应的纵向药物代谢组学：表型、疗效和毒性
Front Oncol. 2020 Nov 12;10:548300. doi: 10.3389/fonc.2020.548300. eCollection 2020.
5
F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiomic features for prediction of epidermal growth factor receptor mutation status and prognosis in patients with lung adenocarcinoma.基于F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描的放射组学特征预测肺腺癌患者表皮生长因子受体突变状态及预后
Transl Lung Cancer Res. 2020 Jun;9(3):563-574. doi: 10.21037/tlcr-19-592.
6
Metabolic characteristics revealing cell differentiation of nasopharyngeal carcinoma by combining NMR spectroscopy with Raman spectroscopy.结合核磁共振光谱与拉曼光谱揭示鼻咽癌细胞分化的代谢特征
Cancer Cell Int. 2019 Feb 18;19:37. doi: 10.1186/s12935-019-0759-4. eCollection 2019.
7
Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.初治晚期肺腺癌中间变性淋巴瘤激酶重排与表皮生长因子受体突变的临床及影像学特征比较
J Thorac Dis. 2017 Oct;9(10):3927-3937. doi: 10.21037/jtd.2017.08.134.
8
Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.计算机断层扫描与表皮生长因子受体突变状态相关的临床特征在 I/II 期肺腺癌。
Thorac Cancer. 2017 May;8(3):260-270. doi: 10.1111/1759-7714.12436. Epub 2017 Apr 6.
9
Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Non-Small Cell Lung Cancer and Its Potential as a Circulating Biomarker.非小细胞肺癌中通过NAT8L过表达实现的癌症特异性N-乙酰天门冬氨酸生成及其作为循环生物标志物的潜力
Cancer Prev Res (Phila). 2016 Jan;9(1):43-52. doi: 10.1158/1940-6207.CAPR-14-0287. Epub 2015 Oct 28.
10
Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation.丙酮酸羧化酶对非小细胞肺癌的增殖至关重要。
J Clin Invest. 2015 Feb;125(2):687-98. doi: 10.1172/JCI72873. Epub 2015 Jan 20.
本文引用的文献
1
Prospects for clinical cancer metabolomics using stable isotope tracers.使用稳定同位素示踪剂进行临床癌症代谢组学的前景。
Exp Mol Pathol. 2009 Jun;86(3):165-73. doi: 10.1016/j.yexmp.2009.01.005. Epub 2009 Jan 20.
2
Isotopomer-based metabolomic analysis by NMR and mass spectrometry.基于同位素异构体的核磁共振和质谱代谢组学分析。
Methods Cell Biol. 2008;84:541-88. doi: 10.1016/S0091-679X(07)84018-0.
3
Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.日本肺腺癌中细支气管肺泡癌非黏液性和黏液性亚型在表皮生长因子受体（EGFR）和K-ras基因突变分析中的差异评估：组织学亚型与基因突变相关性的确认
Am J Clin Pathol. 2007 Jul;128(1):100-8. doi: 10.1309/WVXFGAFLAUX48DU6.
4
5
The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.接受手术切除的非小细胞肺癌患者的生存结果因表皮生长因子受体（EGFR）突变和P21表达情况而异。
Lung Cancer. 2007 Jul;57(1):96-102. doi: 10.1016/j.lungcan.2007.01.027. Epub 2007 Mar 6.
6
Lung cancer incidence in never smokers.从不吸烟者的肺癌发病率
J Clin Oncol. 2007 Feb 10;25(5):472-8. doi: 10.1200/JCO.2006.07.2983.
7
Integrating metabolomics and transcriptomics for probing SE anticancer mechanisms.整合代谢组学和转录组学以探究SE的抗癌机制。
Drug Metab Rev. 2006;38(4):707-32. doi: 10.1080/03602530600959599.
8
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.厄洛替尼用于晚期非小细胞肺癌一线治疗：一项II期研究。
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6049-55. doi: 10.1158/1078-0432.CCR-06-0260.
9
100 years of lung cancer.肺癌的百年历程
Respir Med. 2006 Dec;100(12):2073-84. doi: 10.1016/j.rmed.2006.09.002. Epub 2006 Oct 23.
10
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
Respirology. 2006 Nov;11(6):687-92. doi: 10.1111/j.1440-1843.2006.00887.x.
Zotero 插件